Hudson Bay Capital Management
AMLX icon

Hudson Bay Capital Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Hudson Bay Capital Management’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,340
Closed -$36.6K – 1363
2025
Q1 		$36.6K Buy
+10,340
New +$36.8K ﹤0.01% 1205
2024
Q3 		– Sell
-250,000
Closed -$475K – 847
2024
Q2 		$475K Sell
250,000
-248,000
-50% -$481K ﹤0.01% 643
2024
Q1 		$1.41M Buy
498,000
+37,400
+8% +$489K 0.01% 506
2023
Q4 		$6.78M Sell
460,600
-221,623
-32% -$3.4M 0.04% 261
2023
Q3 		$12.5M Buy
682,223
+391,323
+135% +$8.27M 0.1% 135
2023
Q2 		$6.27M Buy
+290,900
New +$7.86M 0.05% 269

Other funds holding AMLX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Hudson Bay Capital Management's AMLX Position: Q2 2025 in Review

Hudson Bay Capital Management sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2025, closing a stake of 10,340 shares — an estimated $36.6K sold.

Hudson Bay Capital Management first reported a position in AMLX in Q2 2023 and held it in 6 quarters. The position peaked at $12.5M in Q3 2023. 131 funds tracked by Wall St. Rank hold AMLX as of Q2 2025.

  • Hudson Bay Capital Management reported no remaining Amylyx Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Hudson Bay Capital Management sold 10,340 Amylyx Pharmaceuticals shares in Q2 2025, an estimated $36.6K.
  • Hudson Bay Capital Management first reported a position in Amylyx Pharmaceuticals in Q2 2023 and held it in 6 quarters.
  • Hudson Bay Capital Management's Amylyx Pharmaceuticals position peaked at $12.5M in Q3 2023.
  • 131 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2025.

Based on Hudson Bay Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.